Overview

Apatinib Plus XELOX as Neoadjuvant Therapy in Locally Advanced Gastric Cancer

Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
Apatinib plus XELOX regime as Neoadjuvant Therapy in Locally Advanced Gastric Cancer PatientsWith lymph node metastasis
Phase:
Phase 2
Details
Lead Sponsor:
Shanghai Zhongshan Hospital
Treatments:
Apatinib